

Special Issue

Hepatocellular Carcinoma: Clinical Evidence and Emerging Therapeutic Benefits

Message from the Guest Editor

In recent years, the management of patients with hepatocellular carcinoma (HCC) has changed, mainly due to the introduction of immunotherapies, but also due to different patient selection and the possibility of stage migration. However, although patient selection, nutritional aspects, portal hypertension characteristics and multidisciplinary approaches have identified patients with better outcomes, several subjects are resistant to treatment. The aim of this special issue is to understand the mechanisms of treatment resistance and explore new options, also with the use of artificial intelligence, to provide opportunities for effective disease management. This special issue is open to reviews and original research articles by 30 June 2026.

Guest Editor

Dr. Alessandro Loglio

Gastroenterology, Hepatology and Transplantation Division, Papa Giovanni XXIII Hospital, Bergamo, Italy

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/240762

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)